Delving into the Latest Updates on Alfa Wassermann, Inc. with Synapse

A Multicentric Open-label Randomized Controlled Study for Evaluating the Improvement of Endothelial Function in Stage II Peripheral Arterial Obstructive Disease Patients Treated With Sulodexide + Conventional Treatment {CT] Vs CT Alone

A randomized Multicentric open-label controlled trial. The primary objective of the study is to assess the improvement of endothelial function under sulodexide + conventional treatment or conventional treatment alone in patients with Leriche-Fontaine stage II peripheral arterial obstructive disease (systolic ankle brachial index ABI < 0. 9).

开始日期2019-01-31

申办/合作机构

Alfa Wassermann, Inc.

[+1]

EUCTR2011-002821-24-IT / Not yet recruitingN/A

Prospective pharmacodynamic study on patients with moderate, active Crohn’s disease treated with Rifaximin-EIR 400 mg tablets. - RETIC-PD/006/2011

开始日期2011-07-21

申办/合作机构

Alfa Wassermann, Inc.

EUCTR2010-024177-39-IT / Not yet recruitingN/A

Prospective microbiological study on patients with non-constipation IBS treated with rifaximin 550 mg tablets. - ND

开始日期2011-02-01

申办/合作机构

Alfa Wassermann, Inc.

100 项与 Alfa Wassermann, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Alfa Wassermann, Inc. 相关的专利（医药）

登录后查看更多信息

16

项与 Alfa Wassermann, Inc. 相关的文献（医药）

2013-12-01·MLO: medical laboratory observer

What POLs need to know: meeting "meaningful use" criteria for EHR incentives.

Article

作者: Trepagnier, Trip

2009-05-01·MLO: medical laboratory observer

Diabetes mellitus and coronary risk.

Article

作者: Peluso, Richard

2005-02-01·Clinical and Vaccine Immunology

Immunoglobulin G (IgG) Anti-Tissue Transglutaminase Antibodies Used as Markers for IgA-Deficient Celiac Disease Patients

Article

作者: Forooz, Nahal Kazemi ; Hansson, Tony ; Truedsson, Lennart ; Olsson, Martin ; Dahlbom, Ingrid ; Sjöholm, Anders G.

ABSTRACT The role of immunoglobulin A (IgA) anti-tissue transglutaminase antibodies (IgA-tTG) as predictors of untreated celiac disease (CoD) is well documented, and the presence and levels of these antibodies are most accurately monitored with native or recombinant human antigens. However, IgA-deficient CoD patients are not identified by IgA serology, and conflicting results concerning the diagnostic validity of IgG antibodies against gliadin (IgG-AGA), endomysium (IgG-EmA), and tTG (IgG-tTG) have been reported. The aim of the present study was to evaluate the utility of IgG-tTG for the detection of CoD in IgA-deficient patients. Samples from 115 IgA-deficient and 200 IgA-sufficient subjects were collected and tested for the presence of IgA and IgG antibodies against tTG, EmA, and AGA. Antibodies against tTG were measured by an enzyme-linked immunosorbent assay based on recombinant human tTG, and antibodies against EmA were determined by immunofluorescence. The values for IgG-tTG showed a higher correlation (correlation coefficient [ r ] = 0.91) with those for IgG-EmA for the IgA-deficient subjects than for the IgA-sufficient subjects ( r = 0.88). The overall concordance of the positive and negative results between IgG-tTG and IgG-EmA was 97%, and the IgG-tTG assay discriminated between IgG-EmA-positive and -negative subjects with IgA deficiency at a rate of 100%. Elevated levels of IgG-tTG and IgG-EmA were measured in 70% of the IgA-sufficient subjects. IgG-tTG detection with recombinant human tTG is a good alternative to IgG-EmA detection, and the addition of IgG-tTG assessment to present screening methods may improve the ability to identify IgA-deficient subjects with CoD.

100 项与 Alfa Wassermann, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Alfa Wassermann, Inc. 相关的转化医学

登录后查看更多信息